Saxena Mansi, Bhardwaj Nina
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA.
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA; Parker Institute of Cancer Immunotherapy, San Francisco, CA 94129, USA.
Trends Cancer. 2018 Feb;4(2):119-137. doi: 10.1016/j.trecan.2017.12.007.
Dendritic cells (DCs) are essential in immunity owing to their role in activating T cells, thereby promoting antitumor responses. Tumor cells, however, hijack the immune system, causing T cell exhaustion and DC dysfunction. Tumor-induced T cell exhaustion may be reversed through immune checkpoint blockade (ICB); however, this treatment fails to show clinical benefit in many patients. While ICB serves to reverse T cell exhaustion, DCs are still necessary to prime, activate, and direct the T cells to target tumor cells. In this review we provide a brief overview of DC function, describe mechanisms by which DC functions are disrupted by the tumor microenvironment, and highlight recent developments in DC cancer vaccines.
树突状细胞（DCs）在免疫中至关重要，因为它们在激活T细胞方面发挥作用，从而促进抗肿瘤反应。然而，肿瘤细胞会劫持免疫系统，导致T细胞耗竭和DC功能障碍。肿瘤诱导的T细胞耗竭可通过免疫检查点阻断（ICB）来逆转；然而，这种治疗在许多患者中未能显示出临床益处。虽然ICB有助于逆转T细胞耗竭，但DC对于启动、激活T细胞并引导其靶向肿瘤细胞仍然是必需的。在本综述中，我们简要概述了DC的功能，描述了肿瘤微环境破坏DC功能的机制，并重点介绍了DC癌症疫苗的最新进展。
